Medicus Pharma (MDCX) COO awarded 200,000 options at $0.36 exercise price

Rhea-AI Filing Summary

Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith received a grant of stock options covering 200,000 common shares on June 3, 2026. The options have an exercise price of $0.36 per share, vest quarterly in four equal installments over one year, and expire on June 3, 2031. Following this grant, he holds 200,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Smith Andrew Alasdair

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	200,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 200,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 200,000 options Exercise price: $0.36 per share Underlying shares: 200,000 common shares +3 more

6 metrics

Option grant size 200,000 options Stock Option (right to buy) granted June 3, 2026

Exercise price $0.36 per share Conversion or exercise price for the options

Underlying shares 200,000 common shares Underlying security shares for the option grant

Total options after grant 200,000 options Total shares following transaction, held directly

Expiration date June 3, 2031 Option expiration date

Vesting schedule Quarterly over one year Four equal installments per footnote

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.3600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The option is scheduled to vest quarterly in four equal installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Andrew Alasdair

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.36	06/03/2026		A		200,000		(1)	06/03/2031	Common Shares	200,000	$0	200,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for Andrew A. Smith	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Medicus Pharma (MDCX) COO Andrew Smith report on this Form 4?

He reported receiving a grant of 200,000 stock options. These options give him the right to buy Medicus Pharma common shares at a fixed exercise price, reflecting equity-based compensation rather than an open-market stock purchase or sale.

How many stock options did Medicus Pharma (MDCX) grant to its COO?

Medicus Pharma granted 200,000 stock options to its Chief Operating Officer. Each option is linked to one common share, providing potential future ownership if exercised once vesting conditions are met during the specified schedule and before expiration.

What is the exercise price of the Medicus Pharma (MDCX) options granted?

The stock options have an exercise price of $0.36 per share. This price is the fixed amount the COO must pay per share to convert options into common shares once they are vested and exercised before expiration.

When do the Medicus Pharma (MDCX) COO’s stock options vest?

The options are scheduled to vest quarterly in four equal installments over one year. This means 25% of the 200,000 options vest every quarter, aligning the grant with ongoing service over the one-year vesting period.

When do the newly granted Medicus Pharma (MDCX) stock options expire?

The options expire on June 3, 2031. After this expiration date, any unexercised options become worthless, so the COO must exercise vested options before that date to acquire the underlying common shares.

How many Medicus Pharma (MDCX) options does the COO hold after this grant?

Following this transaction, the COO is shown as holding 200,000 stock options directly. This figure represents his derivative position reported in the filing after receiving the new grant, all tied to Medicus Pharma common shares.